FDA Grants Full Approval to Gilead Breast Cancer Drug

FDA Grants Full Approval to Gilead Breast Cancer Drug
Josh Nathan-Kazis
·2 min read

The drug, known as Trodelvy, was developed by the biotech Immunomedics, which Gilead acquired in September for approximately $21 billion.